Form 4: Arvinas Director Receives Stock Options and RSUs

Arvinas Director Edward Moore Kennedy Jr. was granted stock options and restricted stock units on June 24, 2026, with vesting contingent on continued service.

Summary

• Edward Moore Kennedy Jr., a Director at Arvinas, Inc., received a grant of 22,714 stock options and 15,527 Restricted Stock Units (RSUs) on June 24, 2026.
• The stock options have an exercise price of $8.05 and are set to expire on June 23, 2036.
• Both the RSUs and stock options are scheduled to vest in full on the earlier of June 24, 2027, or immediately prior to the first annual stockholders' meeting after the grant date, provided Mr. Kennedy remains in service with the company.
• Following these transactions, Mr. Kennedy beneficially owns 54,957 shares of common stock, with 29,333 shares held indirectly through the Edward M. Kennedy Jr. 2011 Trusts For Children.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard executive compensation practices rather than significant company performance changes.

Positives

• Director Edward Moore Kennedy Jr. received new equity awards (stock options and RSUs), indicating continued investment and alignment with the company's performance.
• The grant of equity suggests management's confidence in the company's future prospects, as vesting is tied to continued service.
• The exercise price of the stock options ($8.05) is below the current market price, offering potential upside for the reporting person.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• Vesting of the granted equity is contingent upon the reporting person's continued service, implying a risk of forfeiture if employment ceases before the vesting date.
• The value of the stock options and RSUs is subject to market fluctuations and the future performance of Arvinas, Inc.'s stock price.

Future Outlook

The vesting of the granted RSUs and stock options is tied to continued service, with full vesting expected by June 24, 2027, or prior to the first annual stockholders' meeting, indicating a forward-looking commitment from the director.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value and long-term company growth.

Stakeholder Impact

• Shareholders: The issuance of equity awards to directors is a standard compensation practice. The potential for future share issuance upon vesting of RSUs and exercise of options could dilute existing shareholdings, but also aligns director interests with long-term shareholder value.
• Employees: The filing does not directly impact employees, but the retention of key directors is generally positive for company stability.
• Management: The filing details compensation for a director, reinforcing standard corporate governance practices.

Next Steps

• Continued service by Edward Moore Kennedy Jr. to meet vesting requirements for RSUs and stock options.
• Potential exercise of stock options upon vesting and favorable market conditions.
• Settlement of RSUs upon vesting, resulting in the issuance of Arvinas, Inc. common stock.

Key Dates

Keywords

Arvinas Inc, ARVN, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Awards, Director Compensation, SEC Filing, Beneficial Ownership